Navigation Links
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Date:2/9/2009

, PRO 2000 had undergone extensive safety testing in several clinical trials involving women and men in the United States, Europe, Africa and India.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(TM); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the R
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
4. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
5. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
6. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
7. Indevus Announces Submission of New Drug Application
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 Perrigo ... commented on the Mylan N.V. ("Mylan") (NASDAQ: MYL ... acquire Perrigo. "Our views of Mylan,s offer ... to be, based on our Board,s careful reflection of ... depend on the limited choices that Mylan has allowed ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Calif., Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... positive preliminary clinical data from its Phase 1 trial ... HIV-infected subjects who are currently on highly active antiretroviral ... suboptimal CD4+ T-cell counts.  The study is designed to ...
... /PRNewswire/ -- Intuity Medical, Inc .™, ... announced that it has secured a $20M credit facility ... and Oxford Finance Corporation . The funds ... commercialize POGO™, a fully-integrated blood glucose monitoring system. ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... / Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists Dr. Elyson and ... just $199, patients can currently receive a one hour treatment of this teeth whitening ... it includes a number of unique features that can turn teeth up to nine ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... ... and their families asked to share stories around men,s health issues , ... Minneapolis, Minnesota (PRWEB) June 15, 2009 -- In ... Scoop is calling on men and their family members to share their health-related experiences ...
... , CHICAGO, June 15 The following statement is attributable ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ... honored that President Obama will speak directly to physicians at ... to health reform this year that provides all Americans with ...
... announced today the first commercial, plant-based diamine oxidase (DAO). Dr. ... that this new diamine oxidase is orders of magnitude more ... is available as a lyophilized powder. Price will be $200 ... test assays to detect spoilage by the presence of histamines ...
... To Be Released Tuesday Show Employer Health Mandate Would Help ... , WASHINGTON, June 15 Hundreds of economists will ... nation,s health care system, and health care experts will release ... a conference call with reporters on Tuesday. , , ...
... delivery of gene therapy suppresses tumors in mice , ... able to fight lung cancer using gene therapy delivered by ... lung cancer that were treated with a vaporized viral vector ... than untreated mice. , Researchers also found that treated mice ...
... JOLLA, Calif., June 15 Transdel Pharmaceuticals, Inc. (OTC ... developing non-invasive, topically administered products, announced that they anticipate ... of Ketotransdel(R) during the third quarter of 2009. ... of a randomized, double-blind, placebo controlled trial to evaluate ...
Cached Medicine News:Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 2Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 3Health News:AMA Committed to Health Reform, Welcomes President Obama 2Health News:Coming Soon: Lung-Cancer Spray? 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... MacularProtect delivers levels of nutrients ... and macular health in the ... The National Eye Institute. MacularProtect ... lutein, an antioxidant found to ...
Oculair (re-formulated Syntrx Complete) is a potent full-spectrum multiple vitamin/mineral/antioxidant dietary supplement that supports the normal aging process. It is designed to reflect the most re...
Medicine Products: